The decline in drug prices affects the selection results of the seventh batch of national organizational drug collection in the "money bag" of patients.

A few days ago, the National Organization Pharmaceutical Cooperation Office announced the results of the seventh batch of national organized drug collection in the seventh batch of national organizational drug collection through Shanghai Sunshine Pharmaceutical Procurement Network.

The coverage of drugs has been further expanded, and the price of drug prices is more rational. The introduction of the "preparation enterprise" mechanism and implementing "till the inter -grade melting" has become a brighter point in this set.

Drug varieties are becoming more and more extensive

The seventh batch of national organizational drugs involved 31 treatment categories, including common diseases such as hypertension, diabetes, anti -infection, and digestive tract diseases, as well as major diseases such as lung cancer, liver cancer, kidney cancer, and bowel cancer.

"Drugs incorporated into the scope of collection are becoming more and more extensive." Chang Feng, Dean of the International Medical Business School of China Pharmaceutical University, believes that this collection covers high blood pressure, diabetes, gastrointestinal diseases and other common diseases and chronic diseases. The anti -release drug antihypertensive drug, which is first included in the key monitoring catalog drug, Yidala's injection, and truly achieved a non -restricted area.

In addition, Changfeng told the China City Daily reporter that in the national organic collection of drugs, the first -line targeted Delonamis capsule capsules of liver cancer decreased by 83%, and the price returned reasonably, which greatly improved the medicinal availability of patients with liver cancer.

According to Chang Feng, this collection also includes special use of special use of antibacterial drugs such as Micronan injection, Michafen net injection, plus cylinder injection, cephalosporin injection dosage form, and set more reasonable proportions of band. In this episode, the collection of patients not only considers the needs of patients, and respects the characteristics of clinical medication.

It is understood that since 2018, the State Medical Insurance Bureau has carried out 7 batches of national centralized drugs for procurement. The seven batches of collections cover a total of 294 kinds of drugs, and the average price of drugs will decrease by more than 50%. The cumulative medical expenses of the first six batches of collection will save more than 260 billion yuan. The seventh batch of collection is expected to save 18.5 billion yuan each year. From the perspective of dosage, the seven batches of collection have accounted for 35%of the annual cost of medical institutions, and centralized procurement has become an important model for drug procurement in medical institutions.

Downside price decrease is more rational

The decline in drug prices directly affects the "money bag" of patients.

In this episode, the first -line targeting Yin Lunbutini capsule of liver cancer drops from an average of 108 yuan to 18 yuan. The patient's treatment cycle can save 8,100 yuan; The price of Tololol's slow -release tablets is 53%, and the burden of medication for patients with hypertension is significantly reduced; Pfizer's Diamondin, Japan Anstelai Mikafen Pure, Emmiro of Spain The 4 original pharmaceuticals including Blekoxin, Italy Bleko, with an average price reduction of 67%.

According to the National Medical Insurance Bureau, it will work with relevant departments to guide all localities and selected enterprises to do a good job of implementing the results of the Chinese elections to ensure that patients across the country use the high -election products after this collection of prices in November this year.

It is worth noting that compared with the average of 53%of the concentrated procurement prices of the first six batch of national drugs, the average price reduction of drugs in this plan was 48%. In Changfeng's view, the decline in the price of medicines in the collection of drugs is the same as the sixth batch of insulin special collection, which is a reasonable level.

The reason why this collection is slightly inferior to the first five batches of collection. The analysis of Changfeng, on the one hand, the company has more profound awareness after multiple collection, the quotation is more reasonable, and it is more inclined to obtain reasonable profits and expectations; On the other hand, before that, some varieties have been included in the local collection variety catalog, and some of the virtual high drug prices have been squeezed, so the seventh batch of price reduction space for the seventh batch of collection is relatively limited.

Yao Yu, deputy director of the Cultural Behavior Laboratory of the Chinese Academy of Social Sciences and a professor at the School of Economics of the Chinese Academy of Social Sciences, expressed similar views in an interview with the China Urban News reporter. In the context of the policy of organizing drugs in the national organization, some pharmaceutical companies are in fact It is already actively cutting prices, and the price reduction space is relatively limited. At the same time, the decline in drug prices has a certain relationship with the variety of drugs.

"In addition, in order to avoid the phenomenon of disconnecting the supply of drugs, there must be enough price space. For example, some drugs selected in the collection are not necessarily produced by our factory, and may be produced by foundry. At this time Potential risks such as rising work costs leave a certain price space. "Yao Yu added.

The rules are more optimized and perfect

In addition to the increasingly wide variety of pharmaceutical varieties, the decline in drug prices is more rational, and the seventh batch of national organizational drug collection has also shown many highlights in the collection rules.

In order to better guarantee the stable supply of collection drugs, the first collection of collection has been clearly introduced in the procurement document to prepare for corporate mechanisms to explore the realization of "one province and double supply".

Specifically, not only one of each of the provinces has one of the companies, that is, the main company, but also one for the company. The selected varieties in the selected enterprises cannot be supplied in a timely and sufficient amount or cancel the qualifications of the selection in a timely manner, which causes the agreement to provide the corresponding election varieties when the agreement cannot continue to be fulfilled.

In Changfeng's view, this collection of "preparation enterprises" mechanism for the first time to explore the realization of "one province and double confession", which will provide direct double guarantees for the timely, stable and smooth supply of the drugs, which further reduces the choice of provinces' choices. Administrative cost of substitute enterprises.

"Preparation of the corporate mechanism will put some pressure on the bidding enterprises and urge them to better complete the supply indicator. Even if the supply is really disconnected, we also have the selection of enterprises to ensure the supply, which is conducive to ensuring the needs of the people's medication." Yao Yu said.

Pharmaceutical strategic marketing expert Shi Lichen said in an interview with the China Urban Daily reporter that compared with the previous selection companies that could not supply collection drugs, the region of the area was temporarily launched. At the beginning, Ji Cai determined that the candidate enterprises were determined, and the stable supply of the collection of collection was ahead of the insurance. It is worth noting that this collection has also introduced the new rules for the first time of the "Fine Molicion". In the past, the "comparable price" ≤ the minimum "unit price" of the same variety was 1.8 times the same as the "unit price" ≤0.1 yuan. The "unit declaration price" decreased one of the three conditions of ≥50%.

The seventh batch of national drug collection is further improved and optimized in related rules. On the basis of meeting one of the above three conditions, if it is a product with the highest level in the same variety, it is also necessary to calculate according to the "highest level of the same variety 'units' comparable prices '/minimum units of the same variety'" The ratio value can be selected in the top 6 of the ratio of the ratio of all varieties.

Chang Feng believes that the introduction of the rules of the "Fine Meltenance" rules compares the difference in the price difference of different varieties at the same level, and controls the price difference of the selected products to about 3 times, which shows that the relevant departments of the collection of collecting and mining are reduced to narrow the price difference in the same variety and reduce the price difference and reduce the reduction in the same variety. Determination of price differences in each province.

In Yao Yu's opinion, the "Fine Molicion" rules are to prevent enterprises from trying to get a high school bid price price after estimating the number of bids in the same variety and the market average price. It reminds enterprises in the process of bidding, to fully consider the lower prices that other manufacturers of the product may report, and they must also bid at a lower price as much as possible.

Forced pharmaceutical companies to accelerate the transformation

In September 2021, the "Fourteenth Five -Year Plan" National Medical Security Plan issued by the General Office of the State Council clearly stated that by 2025, the provinces (autonomous regions, municipalities) national and provincial drug concentrated procurement varieties will be more than 500, high, high, high high, high high Duty medical consumables are concentrated in the procurement variety of more than 5 categories.

With the normalization, institutionalization, and quantity expansion of band purchases, how will companies respond in the future?

Chang Feng believes that one of the targets of collection is to regulate the behavior of pharmaceutical production and circulation enterprises, purify the market environment, and promote the transformation and upgrading of the entire industry. Through the principles of volume procurement and recruitment, the collection has made the most fundamental arrangement from the system in terms of institutional development. Enterprises replace the original gray sales channel competition with quality and price competition. At the same time, supporting policies such as prepaid and guarantee of medical insurance funds have effectively reduced the operating costs of the enterprise and solved the problem of squeezing payment.

"Therefore, on the one hand, the enterprise spontaneously selects a large -scale economic production model to further enlarge and strengthen the scale of scale and leading enterprises, and cannot adapt to the elimination of small enterprises in collecting collection, thereby effectively resolving low -end and invalid capacity; another In terms of, the popular drug circulation and usage are forcing enterprises to turn to innovation -driven and stimulate the endogenous motivation of enterprise innovation. my country has gradually realized the jump of low -level supply and demand balance to high levels of supply and demand. "

CITIC Securities also predicts that the major varieties (including injections) with large clinical drugs and high procurement amounts will no longer be the profit growth point of pharmaceutical companies. Bringing volume is more about the cage and birds that promote medical insurance funds and support for the development of innovative drugs. In the future, the importance of the sales capacity of pharmaceutical companies will gradually weaken, and innovation and transformation are expected to be the main way for pharmaceutical companies to enhance competitiveness.

In the context of the country's encouragement of innovation, my country's pharmaceutical innovation has entered the fast lane, and the number of pharmaceutical research and development investment, the number of new drugs, and the approval of innovative products have shown a rapid increasing situation year by year. Among them, in 2021, my country's innovative medicines and innovative medical devices have been approved by the number of innovation, which is the highest level in the past five years.

Shi Lichen believes that for pharmaceutical companies that do not have research and development capabilities, they are currently working on large -scale production. Chemical generic drugs through the integrated production of raw materials and drug preparations to ensure the stable supply of the company's product raw materials, reduce production costs and ensure product quality In the context of centralized procurement of drugs, a stronger competitive advantage is formed.

At the level of product strategy, Shi Lichen suggested that pharmaceutical companies should lay different products for different market layouts, and the product structure should complement each other. As the state increases the outflow of electronic prescriptions in the separation of medicine, pharmacies, private hospitals, and Internet online drug sales will become a very important competitive market for pharmaceutical companies. Shi Lichen suggested that relevant enterprises have early layout.

■ China City Daily Reporter: Xing Can

- END -